STING1 and cancer: As STING activation not only enhances antitumor immunity but also upregulates immune inhibitory molecules such as PD-L1, the rational combination of a STING ADC with other therapeutics such as immune checkpoint inhibitors is likely to provide better outcomes in cancer treatments.